

---

## PRESS RELEASE



# GLOBAL CANCER TECHNOLOGY

**For Immediate Release**

**Contact:**

info@globalcancertechnology.com

### **GLOBAL CANCER TECHNOLOGY PRESENTS PI3K INHIBITOR DRUG AT SOCIETY OF NEURO ONCOLOGY MEETING**

***POSTER PRESENTATION BY DR. EKOKOBE FONKEM RECIEVES AN  
OVERWHELMING AND ENTHUSIASTIC RESPONSE***

**San Diego, CA, December 10, 2022** – Global Cancer Technology, Inc. today announced their successful poster presentation of their current progress at the 2022 Society of Neuro Oncology meeting in Tampa Florida.

Global Cancer Technology is developing a novel PI3K inhibitor drug to treat a deadly form of brain cancer known as glioblastoma, or GBM.

“It was gratifying to see so many physicians and scientists express their support for the preclinical results that were obtained with our PI3K inhibitor *in vivo* studies” said Dr. Ekokobe Fonkem, chairman of the Neuro oncology department at Baylor Scott & White. “We look forward to conducting a phase I clinical trial in the near future”, Dr. Fonkem added.

“We are proud to demonstrate our PI3K inhibitor drug as a mechanistically distinct, potent, selective and brain-penetrating modulator of PI3K, which is often overly active in difficult to treat tumors, including GBM”, commented Mr. John Clark, the CEO of Global Cancer Technology.

Global Cancer Technologies Chief Scientific Consultant. M. Karen Newell PhD, further added “We are encouraged by our preclinical results to date and are eager to move forward with our next series of studies.”

\*\*\*\*\*

Global Cancer Technology is a non-revenue, preclinical stage company developing a PI3K inhibitor drug to treat a deadly brain disease known as glioblastoma, or GBM. The same drug is also showing great promise in the treatment of triple negative breast cancer.

\*\*\*\*\*  
\*\*\*\*\*

[www.globalcancertechnology.com](http://www.globalcancertechnology.com), providing advanced technologies to the worldwide medical oncology market.

*Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.*